Content area
Abstract
Renal oncocytoma and chromophobe renal cell carcinoma were accepted as unique renal tumors in the late 1990s. Since their formal description, criteria for diagnosis have evolved and additional distinct tumor subtypes originally considered as one these two entities are now recognized. The last two decades have witnessed unprecedented interest in the spectrum of low grade oncocytic renal neoplasms in three specific areas: (1) histologic characterization of tumors with overlapping morphologic features between oncocytoma and chromophobe renal cell carcinoma; (2) description of potentially unique entities within this spectrum, such as eosinophilic vacuolated tumor and low-grade oncocytic tumor; and (3) better appreciation of the association between a subset of low grade oncocytic tumors and hereditary renal neoplasia. While this important work has been academically rewarding, the proposal of several histologic entities with overlapping morphologic and immunophenotypic features (which may require esoteric adjunctive immunohistochemical and/or molecular techniques for confirmation) has created frustration in the diagnostic pathology and urology community as information evolves regarding classification within this spectrum of renal neoplasia. Pathologists, including genitourinary subspecialists, are often uncertain as to the “best practice” diagnostic approach to such tumors. In this review, we present a practical clinically relevant algorithmic approach to classifying tumors within the low grade oncocytic family of renal neoplasia, including a proposal for compressing terminology for evolving categories where appropriate without sacrificing prognostic relevance.
Details



1 University of Tennessee Health Science, Department of Pathology and Laboratory Medicine, Memphis, USA (GRID:grid.267301.1) (ISNI:0000 0004 0386 9246)
2 Cleveland Clinic, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
3 University of Verona, Department of Diagnostic and Public Health, Section of Pathology, Verona, Italy (GRID:grid.5611.3) (ISNI:0000 0004 1763 1124); Department of Pathology, Pederzoli Hospital, Peschiera del Garda, Italy (GRID:grid.513352.3)
4 Department of Urology, and Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
5 City of Hope Comprehensive Cancer Center, Department of Medical Oncology and Therapeutics Research, Duarte, USA (GRID:grid.410425.6) (ISNI:0000 0004 0421 8357)
6 Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952)